Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

483.77 +5.12 (+1.07%)
Streaming Delayed Price Updated: 3:00 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 328,919
Open 480.00
Bid (Size) 483.53 (2)
Ask (Size) 484.01 (4)
Prev. Close 478.65
Today's Range 478.75 - 485.04
52wk Range 341.85 - 510.63
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs

Performance

YTD
+17.73%
+17.73%
1 Month
+3.46%
+3.46%
3 Month
+0.99%
+0.99%
6 Month
+18.35%
+18.35%
1 Year
+39.48%
+39.48%

More News

Read More
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Via Benzinga
3 No-Brainer Stocks to Buy in September
Via The Motley Fool
3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever
Via The Motley Fool
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
Via Benzinga
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
Via Benzinga
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Via The Motley Fool
Biotech And Life Science Sector Update Summer Of 2024
Via Talk Markets
Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics
Via Benzinga
Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead
Via The Motley Fool
Vertex to Participate in Upcoming September Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,900 Today
Via Benzinga
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
Via Benzinga
Biotech Bull Market: 3 Ways To Play It
Via Talk Markets
Topics Economy
Exposures Interest Rates
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings
Via Benzinga
These 2 Incredible Growth Stocks Are Set to Soar This Summer and Beyond
Via The Motley Fool
3 Fantastic Growth Stocks to Buy in August
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotech Stocks to Buy on the Dip: August 2024
Via InvestorPlace
Prediction: These 4 Future Technologies Will Be Millionaire-Makers -- and Here Are the Top Stocks to Buy Now to Profit From Them
Via The Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in August
Via The Motley Fool
The 3 Best Biotech Stocks to Buy in August 2024
Via InvestorPlace
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
From Vertex Pharmaceuticals
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.